Last reviewed · How we verify
Radiopaque Etonogestrel Implant
Radiopaque Etonogestrel Implant is a Progestin-only contraceptive Small molecule drug developed by Organon and Co. It is currently in Phase 3 development for Contraception in women of reproductive age. Also known as: SCH 900415.
A subdermal contraceptive implant that releases etonogestrel (a progestin) to prevent ovulation and thicken cervical mucus, with added radiopaque material for improved visibility on imaging.
A subdermal contraceptive implant that releases etonogestrel (a progestin) to prevent ovulation and thicken cervical mucus, with added radiopaque material for improved visibility on imaging. Used for Contraception in women of reproductive age.
At a glance
| Generic name | Radiopaque Etonogestrel Implant |
|---|---|
| Also known as | SCH 900415 |
| Sponsor | Organon and Co |
| Drug class | Progestin-only contraceptive |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Contraception / Women's Health |
| Phase | Phase 3 |
Mechanism of action
Etonogestrel is a synthetic progestin that suppresses the luteinizing hormone (LH) surge necessary for ovulation and alters cervical mucus consistency to impede sperm transport. The radiopaque formulation incorporates barium sulfate or similar contrast agents to enhance visibility on X-rays and other imaging modalities, improving clinical localization and removal if needed.
Approved indications
- Contraception in women of reproductive age
Common side effects
- Irregular bleeding or amenorrhea
- Headache
- Breast tenderness
- Mood changes
- Insertion site pain or infection
Key clinical trials
- A Study to Assess Contraceptive Efficacy and Safety of Etonogestrel (ENG) Implant Beyond 3 Years of Use (MK-8415-060) (PHASE3)
- Pharmacokinetic Interactions of ENG Subdermal Implants with Long-Acting Cabotegravir (CAB-LA) and LA Rilpivirine (RPV-LA) (CARLA) (PHASE4)
- Impact of Contraceptives on Cervico-Vaginal Mucosa (PHASE4)
- A Multicenter Trial to Evaluate the Insertion Characteristics of the Radiopaque Etonogestrel Implant Using a Next Generation Applicator (34530)(P05702) (PHASE3)
- A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720) (PHASE3)
- Antepartum Etonogestrel Contraceptive Implant Insertion at Term (PHASE1)
- Immediate Postpartum Nexplanon Placement in Opioid Dependent Women
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Radiopaque Etonogestrel Implant CI brief — competitive landscape report
- Radiopaque Etonogestrel Implant updates RSS · CI watch RSS
- Organon and Co portfolio CI
Frequently asked questions about Radiopaque Etonogestrel Implant
What is Radiopaque Etonogestrel Implant?
How does Radiopaque Etonogestrel Implant work?
What is Radiopaque Etonogestrel Implant used for?
Who makes Radiopaque Etonogestrel Implant?
Is Radiopaque Etonogestrel Implant also known as anything else?
What drug class is Radiopaque Etonogestrel Implant in?
What development phase is Radiopaque Etonogestrel Implant in?
What are the side effects of Radiopaque Etonogestrel Implant?
What does Radiopaque Etonogestrel Implant target?
Related
- Drug class: All Progestin-only contraceptive drugs
- Target: All drugs targeting Progesterone receptor
- Manufacturer: Organon and Co — full pipeline
- Therapeutic area: All drugs in Contraception / Women's Health
- Indication: Drugs for Contraception in women of reproductive age
- Also known as: SCH 900415